Opus Genetics (IRD) Company Overview

Profile

Full Name:

Opus Genetics, Inc.

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

January 19, 2015

Indexes:

Not included

Website:

http://opusgtx.com

Description:

Opus Genetics is a biotechnology company focused on developing innovative gene therapies for rare genetic disorders, aiming to improve patient outcomes through advanced medical solutions.

Key Details

Price

$1.15

Market Cap

$36.30 M(Small cap)

Last Dividend

-

TTM Dividend Yield

-

Annual Revenue

$19.05 M(-52.20% YoY)

Annual EPS

-$0.46(-152.87% YoY)

PE Ratio

-

Annual ROE

-20.77%

Annual Debt To Equity

0.00

Beta

1.39

Events Calendar

Earnings

Next earnings date:

Mar 7, 2025

Recent quarterly earnings:

Nov 12, 2024

Recent annual earnings:

Mar 8, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

Nov 6, 2020

Analyst ratings

Recent major analysts updates

Dec 12, 24 HC Wainwright & Co.
Buy
Oct 23, 24 Canaccord Genuity
Buy
Aug 15, 24 HC Wainwright & Co.
Buy
Aug 14, 24 Canaccord Genuity
Buy
May 13, 24 HC Wainwright & Co.
Buy
May 13, 24 Canaccord Genuity
Buy

Screeners with IRD included

Growing Shares Outstanding
US stocks
Stocks with high beta
Biggest stock losers today
Stocks below SMA 200
Most recommended stocks
Best performing stocks last 3 months
Stocks above SMA 50
Stocks below analysts price target
Healthcare sector

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Current Price

$1.15
IRD price is $1.15

Price All-time High

$2880.00
IRD price is currently -99.96% below its historical high of $2880.00

Price Analysts Target

$9.50
IRD price is currently -87.89% lower than the consensus analysts' forecast

Price Most Recent Change

-9.45%
IRD price was down -9.45% on Feb 7, 2025

Price YTD Change

-3.36%
IRD price is down -3.36% since January 1st

Price 3-Year Change

-61.15%
IRD price is down -61.15% over the past 3 years

Market cap

Market Cap

$36.30 M
IRD market capitalization is $36.30 million

Market Cap 3-Year Change

-34.92%
IRD market capitalization is down -34.92% over the past 3 years

Market Cap All-time High

$144.85 M
IRD market capitalization is currently -74.94% below its historical high of $144.85 million

Market Cap Sector Rank

31.69%
IRD market capitalization is higher than 31.69% of companies in Healthcare sector

Technical

Beta

1.39
IRD beta is 1.39

200-day SMA

$1.41
IRD price is currently -18.32% below its 200-day simple moving average

14-day RSI

49.13
IRD 14-day relative strength index is 49.13

30-day Relative Volume

1.34
IRD 30-day relative volume is 1.34

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Annual Revenue

$19.05 M
IRD annual revenue is $19.05 million

Annual Revenue Analysts Estimate

$17.80 M
IRD annual revenue is currently +7.03% higher than the consensus analysts' forecast

Annual Revenue 1-Year Change

-52.2%
IRD annual revenue is down -52.2% year-on-year

Annual Revenue Sector Rank

36.23%
IRD annual revenue is higher than 36.23% of companies in Healthcare sector

Profit

Annual Gross Profit

-
IRD annual gross profit value is unknown

Annual Gross Margin

-
IRD annual gross profit margin value is unknown

Annual Operating Profit

-$10.56 M
IRD annual operating income is -$10.56 million

Annual Operating Margin

-55.45%
IRD annual operating profit margin is -55.45%

Annual Net Income

-$9.99 M
IRD annual net profit is -$9.99 million

Annual Net Margin

-52.42%
IRD annual net profit margin is -52.42%

EPS

Annual EPS

-$0.46
IRD annual earnings per share is -$0.46

Annual EPS Analysts Estimate

-$0.85
IRD annual earnings per share is currently -46.09% lower than the consensus analysts' forecast

Annual EPS 1-Year Change

-152.87%
IRD annual earnings per share is down -152.87% year-on-year

Annual EPS Sector Rank

73.05%
IRD annual earnings per share is higher than 73.05% of companies in Healthcare sector

ROA & ROE

Annual ROA

-19.40%
IRD annual return on assets is -19.40%

Annual ROE

-20.77%
IRD annual return on equity is -20.77%

EBIT & EBITDA

Annual EBIT

-$9.97 M
IRD annual earnings before interest & taxes is -$9.97 million

Annual EBITDA

-$9.97 M
IRD annual EBITDA is -$9.97 million

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PE Ratio

-
IRD price to earnings ratio value is unknown

PE Ratio Sector Rank

-
IRD price to earnings ratio is unknown

PB Ratio

PB Ratio

1.06
IRD price to book ratio is 1.06

PB Ratio Sector Rank

42.73%
IRD price to book ratio is higher than 42.73% of companies in Healthcare sector

PS Ratio

PS Ratio

4.33
IRD price to sales ratio is 4.33

PS Ratio Sector Rank

57.96%
IRD price to sales ratio is higher than 57.96% of companies in Healthcare sector

Enterprise value

Enterprise Value

-$328.23 K
IRD enterprise value is -$328.23 thousand

Enterprise Value Sector Rank

10.04%
IRD enterprise value is higher than 10.04% of companies in Healthcare sector

EV/EBITDA

EV/EBITDA

0.01
IRD EV/EBITDA is 0.01

EV/EBITDA Sector Rank

67.39%
IRD EV/EBITDA is higher than 67.39% of companies in Healthcare sector

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Annual Current Ratio

13.35
IRD annual current ratio is 13.35

Annual Quick Ratio

-
IRD annual quick ratio value is unknown

Leverage

Annual Debt To Equity

0.00
IRD annual debt to equity ratio is 0.00

Annual Interest Coverage Ratio

-
IRD annual interest coverage ratio value is unknown

Risk & Stability

Piotroski F-Score

-
IRD piotroski f-score value is unknown

Altman Z-Score

4.13
IRD altman z-score is 4.13

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Annual Total Assets

$53.95 M
IRD annual total assets is $53.95 million

Annual Non Current Assets

$0.00
IRD annual long term assets is $0.00

Annual Current Assets

$53.95 M
IRD annual total current assets is $53.95 million

Annual Cash & Cash Equivalents

$50.50 M
IRD annual cash & cash equivalents is $50.50 million

Equity

Annual Book Value

$49.91 M
IRD annual book value is $49.91 million

Annual Working Capital

$49.91 M
IRD annual working capital is $49.91 million

Liabilities

Annual Total Liabilities

$4.04 M
IRD annual total liabilities is $4.04 million

Annual Total Long Term Liabilities

$0.00
IRD annual total long term liabilities is $0.00

Annual Current Liabilities

$4.04 M
IRD annual total current liabilities is $4.04 million

Annual Accounts Payable

$2.15 M
IRD annual accounts payable is $2.15 million

Debt

Annual Total Debt

$0.00
IRD annual total debt is $0.00

Annual Total Debt 1-Year Change

0%
IRD {parameterFullLabel} has remained unchanged year-on-year

Annual Long Term Debt

-
IRD annual long term debt value is unknown

Annual Short Term Debt

-
IRD annual short term debt value is unknown

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Annual Total Expenses

$29.61 M
IRD annual total expenses is $29.61 million

Annual Operating Expenses

$29.61 M
IRD annual total operating expenses is $29.61 million

Annual Cost Of Goods Sold

-
IRD annual cost of goods sold value is unknown

Annual SGA

$11.96 M
IRD annual SGA is $11.96 million

Annual D&A

$6000.00
IRD annual depreciation & amortization is $6000.00

Annual Interest Expense

$0.00
IRD annual interest expense is $0.00

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Annual CFO

-$1.11 M
IRD annual cash flow from operations is -$1.11 million

Annual CFO 1-Year Change

-107.77%
IRD annual cash flow from operations is down -107.77% year-on-year

Annual CFI

$0.00
IRD annual cash flow from investing activities is $0.00

Annual CFI 1-Year Change

0%
IRD {parameterFullLabel} has remained unchanged year-on-year

Annual CFF

$8.98 M
IRD annual cash flow from financing activities is $8.98 million

Annual CFF 1-Year Change

+137.16%
IRD annual cash flow from financing activities is up +137.16% year-on-year

Free CashFlow

Annual FCF

-$1.11 M
IRD annual free cash flow is -$1.11 million

Annual FCF 1-Year Change

-107.77%
IRD annual free cash flow is down -107.77% year-on-year

CAPEX

Annual CAPEX

-
IRD annual capital expenditures value is unknown

Annual CAPEX 1-Year Change

-
IRD annual capital expenditures 1-year change is unknown

Institutional Ownership

Similar stocks

UBX logo
Unity Biotechnology (UBX)
CalciMedica (CALC)
IXHL logo
Incannex Healthcare Limited (IXHL)
DTIL logo
Precision BioSciences (DTIL)
NRXP logo
NRx Pharmaceuticals (NRXP)
VYNE logo
VYNE Therapeutics (VYNE)
ATNM logo
Actinium Pharmaceuticals (ATNM)
ATHE logo
Alterity Therapeutics Limited (ATHE)
RLYB logo
Rallybio (RLYB)
Shareholder Group Led by Founder Mina Sooch Nominates Majority Slate of Director Candidates to the Board of Opus Genetics, Inc.
Shareholder Group Led by Founder Mina Sooch Nominates Majority Slate of Director Candidates to the Board of Opus Genetics, Inc.
Shareholder Group Led by Founder Mina Sooch Nominates Majority Slate of Director Candidates to the Board of Opus Genetics, Inc.
IRD
globenewswire.comFebruary 7, 2025

Current Board's Strategic, Management, and Capital Allocation Failures Have Driven an 80% Stock Decline Over Last 22 Months

Opus Genetics Receives FDA Agreement Under Special Protocol Assessment for Phase 3 Trial of APX3330 in Diabetic Retinopathy
Opus Genetics Receives FDA Agreement Under Special Protocol Assessment for Phase 3 Trial of APX3330 in Diabetic Retinopathy
Opus Genetics Receives FDA Agreement Under Special Protocol Assessment for Phase 3 Trial of APX3330 in Diabetic Retinopathy
IRD
globenewswire.comDecember 19, 2024

Agreement Reached on Primary Endpoint and Phase 3 Trial Design Oral APX3330 is a Late-Stage Clinical Asset Available for Partnering FARMINGTON HILLS, Mich., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage ophthalmic biotechnology company developing gene therapies for the treatment of inherited retinal diseases (IRDs) and small-molecule drugs to treat other ophthalmologic disorders, today announced that it has reached agreement with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) for a Phase 3 clinical trial evaluating oral APX3330 for the treatment of moderate to severe non-proliferative diabetic retinopathy (NPDR).

Opus Genetics, Inc. (IRD) Reports Q3 Loss, Tops Revenue Estimates
Opus Genetics, Inc. (IRD) Reports Q3 Loss, Tops Revenue Estimates
Opus Genetics, Inc. (IRD) Reports Q3 Loss, Tops Revenue Estimates
IRD
zacks.comNovember 12, 2024

Opus Genetics, Inc. (IRD) came out with a quarterly loss of $0.29 per share versus the Zacks Consensus Estimate of a loss of $0.30. This compares to earnings of $0.25 per share a year ago.

FAQ

  • What is the ticker symbol for Opus Genetics?
  • Does Opus Genetics pay dividends?
  • What sector is Opus Genetics in?
  • What industry is Opus Genetics in?
  • What country is Opus Genetics based in?
  • When did Opus Genetics go public?
  • Is Opus Genetics in the S&P 500?
  • Is Opus Genetics in the NASDAQ 100?
  • Is Opus Genetics in the Dow Jones?
  • When was Opus Genetics's last earnings report?
  • When does Opus Genetics report earnings?
  • Should I buy Opus Genetics stock now?

What is the ticker symbol for Opus Genetics?

The ticker symbol for Opus Genetics is NASDAQ:IRD

Does Opus Genetics pay dividends?

No, Opus Genetics does not pay dividends

What sector is Opus Genetics in?

Opus Genetics is in the Healthcare sector

What industry is Opus Genetics in?

Opus Genetics is in the Biotechnology industry

What country is Opus Genetics based in?

Opus Genetics is headquartered in United States

When did Opus Genetics go public?

Opus Genetics's initial public offering (IPO) was on January 19, 2015

Is Opus Genetics in the S&P 500?

No, Opus Genetics is not included in the S&P 500 index

Is Opus Genetics in the NASDAQ 100?

No, Opus Genetics is not included in the NASDAQ 100 index

Is Opus Genetics in the Dow Jones?

No, Opus Genetics is not included in the Dow Jones index

When was Opus Genetics's last earnings report?

Opus Genetics's most recent earnings report was on Nov 12, 2024

When does Opus Genetics report earnings?

The next expected earnings date for Opus Genetics is Mar 7, 2025

Should I buy Opus Genetics stock now?

As of today, analysts generally recommend a 'Strong buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions